Big leap innovation cannot be done in isolation. The Ksilink association was established in 2014 in Strasbourg, France with a major objective to build synergies and enabling patient-based drug discovery for precision medicine. Today, Ksilink counts 12 members, 23 employees and runs its own platform applying highly innovative AI-assisted phenotypic profiling methodologies. Ksilink conducts a coherent pipeline of patient-based programs in the field of muscular and neurologic disorders. The non profit Association is financially supported by its members and the French initiative “Programme d’Investissements d’Avenir”.
A synergistic network in the heart of Europe
The 12 members of the Ksilink association are: